JP Morgan Chase
CUVL icon

JP Morgan Chase’s Clinuvel Pharmaceuticals CUVL Stock Holding History

JP Morgan Chase’s Portfolio CUVL Stock Details CUVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$18 Buy
+3
New +$19 ﹤0.01% 7995

Other funds holding CUVL

UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Shade Tree Advisors
Shade Tree Advisors Saratoga Springs, New York $187M AUM 53.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

JP Morgan Chase's CUVL Position: Q3 2026 in Review

JP Morgan Chase opened a new position in Clinuvel Pharmaceuticals (CUVL) in Q3 2026: 3 shares worth $18. The stake represents ﹤0.01% of the portfolio and ranks #7995 among its holdings.

6 funds tracked by Wall St. Rank hold CUVL as of Q3 2026.

  • JP Morgan Chase held 3 shares of Clinuvel Pharmaceuticals worth $18 as of Q3 2026.
  • Clinuvel Pharmaceuticals was a new JP Morgan Chase position in Q3 2026.
  • Clinuvel Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #7995 holding.
  • 6 funds tracked by Wall St. Rank held Clinuvel Pharmaceuticals as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.